Worldwide HealthcareWWH:LSE

4.00 / 0.29%
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Aug 20 2014 15:17 BST.

Total returns on £1000

Fund / BenchmarkChange
PriceWorldwide Healthcare (Ordinary Share)+23.87%
Worldwide Healthcare (Ordinary Share)+30.80%
Morningstar's BenchmarkFTSE World+9.91%
As of Aug 18 2014.

Worldwide Healthcare summary

Shares outstanding49.64m
Market cap658.30m GBP
Total assets772.60m GBP
Total expense ratio1.01%
Day high1,369
Day low1,352
Previous close1,360
Average volume55.51k
YTD Change+10.09 %
Diluted NAV (est)1,459.43
Diluted NAV (last pub)1,451.96
Premium/Discount-6.81 %
Gearing+111.00 %
52-week range
Aug 20 2013
Feb 28 2014

As of last trade WWH:LSE traded at 1,364, 3.13% below its 52-week high of 1,408, set on Feb 28, 2014.

Data delayed at least 15 minutes, as of Aug 20 2014 15:17 BST.


Management group(s)OrbiMed Capital LLC
AIC sectorSector Specialist: Biotechnology/Life Sciences
Launch date28 Apr 1995
Share typeOrdinary Share
Base currencyGBP


To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.

Management & contract fees

Frostrow Capital LLP receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to GBP150m, 0.20% p.a. of the market capitalisation in excess of GBP150m and up to GBP500m, and 0.125% p.a. of the market capitalisation in excess of GBP500m, plus a fixed amount equal to GBP 57,500 per annum. Performance fee 16.5% of out-performance of NAV over the benchmark, lower of benchmark at quarter end date and at corresponding quarter end in previous year.


Div yield1.22549
Div ex-date04 Jun 2014
Div pay-date04 Jul 2014

Managed by

Samuel. D Isaly Start : 26 Feb 2009
Data delayed at least 15 minutes, as of Aug 20 2014 15:17 BST.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.